Osimertinib

Drug Profile

Osimertinib

Alternative Names: AZD-9291; Mereletinib; TAGRISSO

Latest Information Update: 13 Oct 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator AstraZeneca
  • Developer AstraZeneca; Dana-Farber Cancer Institute; Eli Lilly; European Thoracic Oncology Platform; Incyte Corporation; Kyushu University; National Cancer Institute (USA); National University Hospital (Singapore); Singapore Clinical Research Institute
  • Class Acrylamides; Aniline compounds; Antineoplastics; Dimethylamines; Indoles; Pyrimidines; Small molecules
  • Mechanism of Action Epidermal growth factor receptor antagonists; Protein tyrosine kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Non-small cell lung cancer
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Non-small cell lung cancer
  • Phase II Carcinomatous meningitis
  • Phase I Solid tumours

Most Recent Events

  • 09 Oct 2017 Osimertinib receives Breakthrough Therapy status for Non-small cell lung cancer (Late-stage disease, First-line therapy) in USA
  • 10 Sep 2017 Efficacy and adverse events data from the phase III FLAURA trial in Non-small cell lung cancer released by AstraZeneca
  • 08 Sep 2017 Pooled safety and efficacy data from the phase II AURA2 and AURA extension trials in Non-small cell lung cancer presented at the 42nd European Society for Medical Oncology Congress (ESMO-2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top